Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RNAi Therapeutic”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Early research (Phase 1)Study completedNCT01814839
What this trial is testing

A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 85
Testing effectiveness (Phase 2)Study completedNCT02595983
What this trial is testing

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

Who this might be right for
Transthyretin (TTR)-Mediated AmyloidosisFamilial Amyloidotic Polyneuropathy (FAP)ATTR Amyloidosis+1 more
Alnylam Pharmaceuticals 12
Early research (Phase 1)Study completedNCT02314442
What this trial is testing

An Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Who this might be right for
Hypercholesterolemia
Alnylam Pharmaceuticals 70
Large-scale testing (Phase 3)Study completedNCT03681184
What this trial is testing

Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Who this might be right for
Primary Hyperoxaluria Type 1 (PH1)
Alnylam Pharmaceuticals 39
Testing effectiveness (Phase 2)Study completedNCT02706886
What this trial is testing

Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1

Who this might be right for
Primary Hyperoxaluria Type 1 (PH1)
Alnylam Pharmaceuticals 52
Testing effectiveness (Phase 2)UnknownNCT01676259
What this trial is testing

SiG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Ductal AdenocarcinomaPancreatic Cancer
Silenseed Ltd 80
Not applicableLooking for participantsNCT04561518
What this trial is testing

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Who this might be right for
Transthyretin-Mediated AmyloidosisATTR Amyloidosis
Alnylam Pharmaceuticals 1,500
Early research (Phase 1)Ended earlyNCT02826018
What this trial is testing

ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

Who this might be right for
Hepatitis BChronic Hepatitis BHepatitis B, Chronic+2 more
Alnylam Pharmaceuticals 24
Large-scale testing (Phase 3)Study completedNCT03417245
What this trial is testing

Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Who this might be right for
Hemophilia AHemophilia B
Genzyme, a Sanofi Company 120
Large-scale testing (Phase 3)Study completedNCT03997383
What this trial is testing

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 360
Testing effectiveness (Phase 2)Study completedNCT02250612
What this trial is testing

SYL040012, Treatment for Open Angle Glaucoma

Who this might be right for
Open Angle GlaucomaOcular Hypertension
Sylentis, S.A. 184
Testing effectiveness (Phase 2)Looking for participantsNCT06659640
What this trial is testing

Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Who this might be right for
Hereditary Hemorrhagic Telangiectasia
Alnylam Pharmaceuticals 120
Testing effectiveness (Phase 2)Study completedNCT03847909
What this trial is testing

Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Who this might be right for
Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney Diseases+2 more
Novo Nordisk A/S 35
Testing effectiveness (Phase 2)WithdrawnNCT03303313
What this trial is testing

An Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

Who this might be right for
Atypical Hemolytic Uremic Syndrome
Alnylam Pharmaceuticals
Early research (Phase 1)Study completedNCT03505853
What this trial is testing

Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)

Who this might be right for
Acute Intermittent Porphyria (AIP)Acute Hepatic Porphyria (AHP)Porphyria, Acute Intermittent+1 more
Alnylam Pharmaceuticals 10
Large-scale testing (Phase 3)Looking for participantsNCT07052903
What this trial is testing

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals 1,250
Large-scale testing (Phase 3)Study completedNCT02510261
What this trial is testing

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
Amyloidosis
Alnylam Pharmaceuticals 211
Not applicableNo Longer AvailableNCT05505838
What this trial is testing

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin-mediated Amyloidosis With CardiomyopathyATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Testing effectiveness (Phase 2)WithdrawnNCT03999840
What this trial is testing

Eculizumab to Cemdisiran Switch in aHUS

Who this might be right for
Atypical Hemolytic Uremic Syndrome
Mario Negri Institute for Pharmacological Research
Large-scale testing (Phase 3)Enrolling By InvitationNCT06679946
What this trial is testing

Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 700
Load More Results